8-K: Integrated BioPharma Reports Q4 Loss Amid Revenue Decline

Integrated BioPharma, Inc. reported a net loss of $0.8 million for the quarter ended December 31, 2025, as revenue decreased by 10.3% to $11.3 million.

Summary

• Revenue for the quarter ended December 31, 2025, was $11.3 million, a 10.3% decrease from $12.6 million in the quarter ended December 31, 2024.
• The company reported an operating loss of $0.9 million in the quarter ended December 31, 2025, compared to an operating income of $0.2 million in the prior year's quarter.
• Net loss for the quarter ended December 31, 2025, was $0.8 million, a significant decline from net income of $0.1 million in the quarter ended December 31, 2024.
• Diluted net loss per share was $(0.03) for the quarter ended December 31, 2025, down from $0.00 per share in the prior year's quarter.
• For the six-month period ended December 31, 2025, revenue decreased by 8.4% to $24.0 million from $26.2 million in the same period of 2024.
• The six-month period also saw an operating loss of $0.7 million and a net loss of $0.6 million, compared to operating income of $0.7 million and net income of $0.4 million in the prior year's six-month period.
• Revenue from the two largest customers in the Contract Manufacturing Segment represented approximately 89% of total revenue for the six months ended December 31, 2025, an increase from 82% in the prior year period.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a significantly negative report, marked by substantial declines in revenue and a shift from profitability to losses across both quarterly and six-month periods, indicating deteriorating financial performance.

Negatives

• 10.3% decrease in quarterly revenue, falling by $1.3 million from $12.6 million to $11.3 million.
• Shift from an operating income of $0.2 million to an operating loss of $0.9 million for the quarter.
• Shift from a net income of $0.1 million to a net loss of $0.8 million for the quarter.
• Diluted net loss per share of $(0.03) for the quarter, a decline from $0.00.
• 8.4% decrease in six-month revenue, falling by $2.2 million from $26.2 million to $24.0 million.
• Shift from an operating income of $0.7 million to an operating loss of $0.7 million for the six-month period.
• Shift from a net income of $0.4 million to a net loss of $0.6 million for the six-month period.
• Diluted net loss per share of $(0.02) for the six-month period, a decline from $0.01.
• Increased customer concentration, with the two largest customers accounting for 89% of total revenue for the six months ended December 31, 2025, up from 82% in the prior year, indicating higher business risk.

Risks

• Changes in general economic and business conditions.
• Loss of market share through competition.
• Introduction of competing products by other companies.
• The timing of regulatory approval and the introduction of new products by INBP.
• Changes in industry capacity.
• Pressure on prices from competition or from purchasers of INBP's products.
• Regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry.
• Regulatory obstacles to the introduction of new technologies or products that are important to INBP.
• Availability of qualified personnel.
• The loss of any significant customers or suppliers.
• Inflation, including inflationary pressures from any tariffs, and tightened labor markets.
• Ability to expand the customer base.
• Further risks and uncertainties described in the section entitled Risk Factors in INBP's most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q.

Future Outlook

The filing contains standard boilerplate language regarding forward-looking statements, indicating that such statements involve risks and uncertainties that could cause actual results to differ materially. No specific future guidance or estimates are provided.

Management Comments

• "Our revenue decreased by approximately 8% in the six-month period ended December 31, 2025 from the six-month period ended December 31, 2024 and our revenue from our two largest customers in our Contract Manufacturing Segment represented approximately 89% and 82% of total revenue in the six months ended December 31, 2025 and 2024, respectively." (Co-Chief Executive Officers Riva Sheppard and Christina Kay)

Industry Context

StockSavvy.ai notes that the nutraceutical and pharmaceutical manufacturing industries are subject to intense competition, regulatory changes, and pricing pressures. INBP's reported revenue decline and shift to operating and net losses, coupled with increased customer concentration, suggest it may be struggling to navigate these industry challenges effectively or facing specific competitive headwinds.

Stakeholder Impact

• Shareholders: Negative impact due to significant decline in revenue, shift to net losses, and negative earnings per share, potentially leading to decreased share value.
• Employees: Potential for future impact if financial performance continues to decline, though no direct mention of layoffs or hiring freezes.
• Customers: Increased customer concentration (89% from two largest customers) suggests a higher risk if one of these key relationships deteriorates.
• Suppliers: No direct impact mentioned, but sustained losses could eventually affect payment terms or order volumes.
• Creditors: Deteriorating financial health could raise concerns about the company's ability to service debt, though no specific debt information is provided.

Key Dates

Recommendation

The company reported significant declines in revenue and a shift from profitability to substantial losses for both the quarter and the six-month period. This indicates a deteriorating financial position. The increased customer concentration also presents a heightened risk. Given the negative financial performance and lack of positive outlook or mitigating factors, a seasoned investor would likely recommend a strong sell.

Keywords

Integrated BioPharma, INBP, Financial Results, Quarterly Report, Nutritional Supplements, Vitamins, Herbal Products, Contract Manufacturing, SEC Filing, Earnings Report, Biopharma